MUMBAI, India and NAPLES, Fla., May 13, 2026
Global pharmaceutical company Lupin Limited announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL) Single-Dose Vials. The approval strengthens Lupin’s expanding U.S. injectable portfolio and reinforces the company’s position in the global generic pharmaceuticals market.
The newly approved product is bioequivalent to the reference listed drug Pepcid® Injection developed by Merck Sharp & Dohme Corp. Famotidine Injection is commonly used in hospitalized patients for the treatment of multiple gastrointestinal conditions, including active duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), and pathological hypersecretory disorders such as Zollinger-Ellison Syndrome. Lupin confirmed that the injectable product will be manufactured at the company’s advanced manufacturing facility in Nagpur, India.
FDA Approval Expands Lupin’s Injectable Portfolio
The FDA approval represents another important milestone in Lupin’s strategy to expand its presence within the U.S. hospital and injectable medicines market. Injectable generic drugs continue to play a critical role in hospital care due to their widespread use in acute treatment settings and their importance in ensuring cost-effective patient access to essential therapies.
Famotidine Injection is specifically indicated for intravenous use in patients who are unable to take oral medication or who require short-term hospital-based treatment for acid-related gastrointestinal conditions. Healthcare providers frequently utilize injectable famotidine in hospital settings to manage excess gastric acid secretion, ulcer healing, and severe reflux symptoms.
Advertisement
According to industry estimates cited by Lupin, Famotidine Injection generated approximately USD 8.7 million in annual U.S. sales for the twelve months ending March 2026. The approval provides Lupin with an opportunity to strengthen its participation in the competitive U.S. gastrointestinal therapeutics market while expanding access to affordable generic injectable treatments.
The company stated that the product approval reflects its continued focus on developing high-quality generic medicines capable of addressing major therapeutic needs across global healthcare markets. Lupin has increasingly emphasized complex generics, injectable formulations, and specialty pharmaceutical products as part of its long-term growth strategy.
Gastrointestinal Therapy Demand Continues to Grow
Famotidine belongs to a class of medications known as histamine-2 receptor antagonists (H2 blockers), which reduce stomach acid production and help manage several acid-related gastrointestinal disorders. Injectable formulations are particularly important for hospitalized patients who require immediate symptom management or cannot tolerate oral medications.
Gastrointestinal diseases remain among the most commonly treated conditions worldwide, with disorders such as GERD, gastric ulcers, and acid hypersecretion affecting millions of patients annually. Rising hospitalization rates, aging populations, and increasing prevalence of digestive disorders continue to drive demand for effective hospital-based gastrointestinal therapies.
Healthcare experts note that generic injectable medications are becoming increasingly important within healthcare systems seeking to improve affordability and maintain stable access to essential hospital medicines. FDA approvals for generic injectables also help support supply chain resilience and reduce dependence on limited suppliers for critical therapies.
Lupin’s manufacturing facility in Nagpur, India, plays a key role in the company’s global production network and supports the development and commercialization of multiple injectable and complex pharmaceutical products for international markets.
Lupin Strengthens Global Generic Drug Leadership
Lupin remains one of India’s largest pharmaceutical companies, with operations spanning more than 100 global markets and a broad portfolio covering branded formulations, generic medicines, biotechnology products, and active pharmaceutical ingredients. The company maintains a particularly strong presence in the United States across multiple therapy areas including respiratory disease, cardiovascular medicine, anti-infectives, gastrointestinal disorders, and central nervous system treatments.
Industry analysts continue to identify FDA approvals as a major driver of growth for global generic drug manufacturers, particularly within the injectable medicines segment where regulatory compliance, manufacturing quality, and supply reliability are critical competitive advantages.
The latest FDA approval further strengthens Lupin’s expanding U.S. pharmaceutical portfolio while supporting the company’s broader strategy of delivering cost-effective hospital therapies and expanding access to essential medicines across global healthcare systems.
Source: Lupin press release
